ArticleJACC. Case reports2025
Rechallenging Patients With Fluoropyridine-Induced Coronary Vasospasm: 5 Success Stories.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effective management of 5-fluorouracil-induced coronary vasospasm allowing chemotherapy continuation: a single-center observational study.Cardio-oncology (London, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients on fluoropyrimidines (5-fluorouracil, capecitabine) for solid organ cancers typically present with chest pain syndromes due to drug-induced coronary vasospasm. Given the potential for life-threatening ischemia, emergent evaluation is warranted. We propose the following approach for diagnosis and management when encountering these patients in inpatient/emergency settings. Evaluation initially includes electrocardiogram and troponin testing (preferably high sensitivity) to rule out acute coronary syndrome, followed by coronary evaluation (computed tomography angiography or left heart catheterization) based on patient acuity. Exercise stress testing is contraindicated in active coronary spasm to avoid exacerbating ischemia and inducing ventricular arrhythmias. Once fluoropyrimidine-associated vasospasm is definitively diagnosed, rechallenge using a standardized vasodilatory premedication protocol in conjunction with multidisciplinary support is both feasible and effective, as evidenced by the successful outcomes in our 5 patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.